Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy A Yap

Showing results (171-180 of 260) with videos related to

Pageof 26
Sort By:
The Oncologist|July 21, 2021
First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid TumorsKhanh T Do, Laura Quan Man Chow, Karen Reckamp, et al.
NPJ Precision Oncology|April 10, 2026
Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 studyJacopo Venturini, Mehmet A Baysal, Abhijit Chakraborty, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unitDionysis Papadatos-Pastos, Desam Roda, Maria Jose De Miguel Luken, et al.
Cancer Chemotherapy and Pharmacology|June 14, 2023
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutationSarina A Piha-Paul, Chieh Tseng, Hai T Tran, et al.
NPJ Precision Oncology|January 13, 2026
Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD AndersonJeong Uk Lim, Heather Y Lin, Lei Kang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2017
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trialsAngela George, Rebecca Kristeleit, Saeed Rafii, et al.
The Oncologist|March 30, 2021
Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical TrialsRyan W Huey, Goldy C George, Penny Phillips, et al.
Radiology|March 17, 2017
Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR ImagingJessica M Winfield, Nina Tunariu, Mihaela Rata, et al.
Cell Reports. Medicine|December 3, 2024
UBA1 inhibition sensitizes cancer cells to PARP inhibitorsSharad Awasthi, Lacey E Dobrolecki, Christina Sallas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumorsTimothy A Yap, Li Yan, Amita Patnaik, et al.
Pageof 26

Showing results (171-180 of 260) with videos related to

Sort By:
Pageof 26
The Oncologist|July 21, 2021
First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid TumorsKhanh T Do, Laura Quan Man Chow, Karen Reckamp, et al.
NPJ Precision Oncology|April 10, 2026
Outcomes of patients with or without DNA repair pathway alterations: the MD Anderson IMPACT2 studyJacopo Venturini, Mehmet A Baysal, Abhijit Chakraborty, et al.
European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unitDionysis Papadatos-Pastos, Desam Roda, Maria Jose De Miguel Luken, et al.
Cancer Chemotherapy and Pharmacology|June 14, 2023
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutationSarina A Piha-Paul, Chieh Tseng, Hai T Tran, et al.
NPJ Precision Oncology|January 13, 2026
Therapeutic responses in patients with advanced NSCLC enrolled in early-phase clinical trials at MD AndersonJeong Uk Lim, Heather Y Lin, Lei Kang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2017
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trialsAngela George, Rebecca Kristeleit, Saeed Rafii, et al.
The Oncologist|March 30, 2021
Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical TrialsRyan W Huey, Goldy C George, Penny Phillips, et al.
Radiology|March 17, 2017
Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR ImagingJessica M Winfield, Nina Tunariu, Mihaela Rata, et al.
Cell Reports. Medicine|December 3, 2024
UBA1 inhibition sensitizes cancer cells to PARP inhibitorsSharad Awasthi, Lacey E Dobrolecki, Christina Sallas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumorsTimothy A Yap, Li Yan, Amita Patnaik, et al.
Pageof 26